concept · intermediate · partly written
Oral absorption and the Biopharmaceutics Classification System
A swallowed drug must dissolve and cross the gut wall, and the classification system sorts drugs by whether solubility or permeability is the limit.
Also called: BCS
The short version
A tablet must dissolve, cross the gut wall and survive two sets of enzymes before reaching the circulation. The classification sorts drugs by solubility and permeability; carriers along the gut can change where in the gut a drug is absorbed. 12
Reported, not yet replicated
The gates more
Dissolution follows the Noyes-Whitney relation: smaller particles raise surface area, low solubility slows everything. The gut wall is crossed by passive diffusion or by a carrier whose density varies along the gut; P-gp can return drug to the lumen and CYP3A4 acts on the same molecule inside the cell. For midazolam the last two gates each removed about 43 to 44 percent. Because the gates are in series, a 20 percent change in any one moves F by 20 percent. 34
Reported, not yet replicated
Where the classification and its assays break more
ICH M9 allows Caco-2 for a high-permeability claim only if passive transport is shown (concentration independence and an efflux ratio below 2, with at least five model drugs per permeability class). The 250 mL criterion does not hold for paediatric patients and BCS does not account for transporter effects. A dissolution-limited drug can fail silently if a less soluble crystal form appears; that case was seen only in a trade article and is not described here. 13
Reported, not yet replicated
Plain answer
Oral bioavailability is a product of four gates: the dose dissolves, the drug crosses the gut wall (Fa), survives gut-wall enzymes (Fg) and survives the liver (Fh). The BCS combines solubility and permeability into four classes: class II (poor solubility, good permeability) is dissolution-limited and class III permeability-limited. Carriers can decide absorption alone: in rats gaboxadol was about 81 to 91 percent absorbed upstream and about 4 percent from the colon. 132
Reported, not yet replicated
Why it matters
Equation
Noyes-Whitney dissolution: dC/dt = D x S x (Cs - Cb) / (V x h), with diffusion coefficient D, surface area S, solubility at the particle surface Cs, bulk concentration Cb, volume V and diffusion-layer thickness h. Oral bioavailability: F = Fa x Fg x Fh.
Real numbers
ICH M9 definitions
High solubility: the highest single dose dissolves in 250 mL or less at pH 1.2 to 6.8 and 37 C. High permeability: absolute bioavailability of 85 percent or more (or 85 percent in urine). A review gave 90 percent and pH 1.2 to 7.5; use the regulatory text. 13
Established
Carrier-limited absorption
Gaboxadol about 81 to 91 percent absorbed from stomach, duodenum or jejunum in rats and about 4 percent from the colon, tracking PAT1; abstract-level. 2
Reported, not yet replicated
A prodrug through a transporter
Valacyclovir is nearly completely converted to acyclovir; acyclovir absolute bioavailability 54.5 percent +/- 9.1 percent (12 volunteers); PepT1-knockout mice had acyclovir Cmax 4 to 6-fold and AUC 2 to 3-fold lower. 56
Reported, not yet replicated
Gut and liver in series
Midazolam: gut extraction 0.43, hepatic 0.44 in 20 healthy subjects. 4
Reported, not yet replicated
In vitro to human absorption, 14 drugs
Log-linear fit to human fraction absorbed: R-squared 0.805 for Caco-2 and 0.664 for Franz-cell PAMPA. 7
Reported, not yet replicated
Still open here
- Human gut transit times and fluid volumes from a primary source.
- Human PEPT1 expression versus valacyclovir PK: only a search summary was seen.
- Polymorph-driven dissolution failures from a primary source.
Linked from
Sources
- ICH M9: Biopharmaceutics Classification System-based biowaivers, Step 5. ICH, via PMDA (2020). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Broberg ML, Holm R, Tønsberg H, Frølund S, et al. Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol. Br J Pharmacol (2012). paper; opened 2026-11-17 all records citing this
- B Shekhawat P, B Pokharkar V. Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles. Acta Pharm Sin B (2017). paper; opened 2026-11-17 all records citing this
- Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther (1996). paper; opened 2026-11-17 all records citing this
- Valacyclovir prescribing information (FDA label, 2008 file). US Food and Drug Administration (2008). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Yang B, Hu Y, Smith DE. Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice. Drug Metab Dispos (2013). paper; opened 2026-11-17 all records citing this
- de Souza Teixeira L, Vila Chagas T, Alonso A, Gonzalez-Alvarez I, et al.. Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs. Pharmaceutics (2020). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/concepts/oral-absorption-and-bcs.json